XML 33 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2010
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2015
Mitsubishi Tanabe        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative agreement upfront payment received       $ 30,000,000
Collaborative agreement maximum additional payment to receive       85,000,000
Patent rights period   The longer of ten years or the life of the related patent rights.    
Clinical trial cost       12,000,000
Collaborative arrangement right description   Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company.    
Collaboration termination notice period   180 days    
Revenues recognized under collaboration agreement   $ 0 $ 0 19,800,000
Deferred revenues under collaboration       $ 10,200,000
AbbVie        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative agreement upfront payment received $ 75,000,000      
Patent rights period   Ten years or the life of the related patent rights.    
Collaborative arrangement right description   The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.    
Collaboration termination notice period   180 days    
Revenues recognized under collaboration agreement   $ 0 $ 15,000,000  
Amount remains outstanding under collaboration agreement   485,000,000    
AbbVie | Development and Regulatory Milestone Payments        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative agreement maximum additional payment to receive   480,000,000    
Collaborative agreement payment received   45,000,000    
AbbVie | Commercial Milestone Payments        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaborative agreement maximum additional payment to receive   $ 50,000,000